QN-023a

DRUG2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Zhejiang University

Conditions

AML, Adult

Phase 1

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

TerminatedNCT05601466

Institute of Hematology & Blood Diseases Hospital, ChinaAML, Adult

Start: 2022-03-26End: 2023-04-11Updated: 2024-11-06

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Zhejiang UniversityAML, Adult

Start: 2022-12-24End: 2025-12-24Target: 19Updated: 2023-01-03